Curon makes cuts and focuses on top line growth
This article was originally published in Clinica
Executive Summary
Curon Medical, which develops proprietary products for the treatment of gastrointestinal disorders, is cutting 17% of its workforce, as well as making further cuts in its operating expenses. The measures come just a week after the company's president and CEO, John Morgan, resigned. The Sunnyvale, California-based company's chairman, Michael Berman, is assuming the position of CEO on an interim basis.
You may also be interested in...
Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says
The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.
The Aspirin Test For AI?
US FDA Commissioner Robert Califf tells Congress that regulators don’t have to know how artificial intelligence works in medicine, but must make very sure it actually does work.
Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire
Clarke helped launch GDUFA I and negotiate GDUFA II, chaired the CDER Executive Committee and oversaw many other programs in the US FDA’s drugs center.